Highlights Hwail Pharmaceutical Co.,Ltd.

Equities

A061250

KR7061250007

End-of-day quote Korea S.E. Other stock markets 23:00:00 23/06/2024 BST			5-day change	1st Jan Change
1,425 ^KRW	-3.52%		-2.80%	-35.37%

04-18	Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 19.0999977 billion in funding from Osung Advanced Materials Co., Ltd., Kumho HT, Inc., CrystalGenomics Invites Co., LTD.	CI
03-27	PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on August 21, 2023.	02-21	CI
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on August 21, 2023.	02-21	CI
Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback announced on August 21, 2023, has expired with 2,340,000 shares, representing 3.52% for KRW 4,980.33 million.	02-19	CI
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on August 21, 2023.	11-21	CI
Hwail Pharmaceutical Co.,Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.	21/08/23	CI
Hwail Pharmaceutical Co.,Ltd. authorizes a Buyback Plan.	20/08/23	CI
CrystalGenomics, Inc. agreed to acquire 20.43% stake in PanGen Biotech Inc. from the group of shareholders for approximately KRW24 billion.	21/11/22	CI
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on March 16, 2022.	19/09/22	CI
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on March 16, 2022.	19/09/22	CI
Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback announced on March 16, 2022, has expired with 1,519,180 shares, representing 2.23% for KRW 4,999.11 million.	18/09/22	CI
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on March 16, 2022.	17/06/22	CI
Hwail Pharmaceutical Co.,Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.	16/03/22	CI
Hwail Pharmaceutical Co.,Ltd. authorizes a Buyback Plan.	15/03/22	CI
Topazio New Technology Association No. 23, Anello New Technology Association No. 22, Bledor New Technology Association No. 24 and IASYS New Technology Association No. 25 completed the acquisition of 15.53% stake in Hwail Pharmaceutical Co.,Ltd. from CrystalGenomics, Inc..	10/01/21	CI
Topazio New Technology Association No. 23, Anello New Technology Association No. 22, Bledor New Technology Association No. 24 and IASYS New Technology Association No. 25 signed a contract to acquire 15.53% stake in Hwail Pharmaceutical Co.,Ltd. from CrystalGenomics, Inc. for KRW 32.4 billion.	18/11/20	CI
DiNonA Inc. completed the acquisition of 9.25% stake in Hwail Pharmaceutical Co.,Ltd. from Park, Pil Joon.	29/09/20	CI
DiNonA Inc. agree to acquire 9.25% stake in Hwail Pharmaceutical Co.,Ltd. from Park, Pil Joon for KRW 30.8 billion	16/09/20	CI
Tranche Update on Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback Plan announced on April 11, 2005.	17/10/18	CI
Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback announced on April 11, 2005, has expired with 1,655,858 shares, representing 32.86% for KRW 12,414.38 million.	11/10/18	CI
Hwail Pharmaceutical Co.,Ltd.'s Equity Buyback announced on April 7, 2011, has expired.	04/04/18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Hwail Pharmaceutical Co.,Ltd.

Equities

A061250

KR7061250007

Highlights

Filters